A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with type 1 diabetes. Skip to main content Open menu Close menu ...

The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School of Medicine suggests.

For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...

A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway found a 45% lower risk in ...

A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared with sodium-glucose cotransporter-2 (SGLT-2) inhibitors ...

Semaglutide, the active ingredient in Ozempic, and other drugs in the same class have revolutionized the treatment of obesity and type 2 diabetes.Now, a clinical trial suggests the medicines can ...